Article
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Breast cancer research and treatment - 1 Oct 2015
Dezentjé V O, Opdam F L, Gelderblom H, Hartigh den J, Van der Straaten T, Vree R, Maartense E, Smorenburg C H, Putter H, Dieudonné A S, Neven P, Van de Velde C J H, Nortier J W R, Guchelaar H-J
Abstract excerpt
Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels may benefit less from tamoxifen treatment. CYP2D6 poor and intermediate metabolizers may need a personalized increased tamoxifen dose to achieve effective endoxifen serum concentrations, without increasing toxicity. From a prospective study population of early breast cancer patients using tamoxifen (CYPTAM:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.